Liquid Chromatography‐Electrospray Mass Spectrometry Determination of Imatinib and Its Main Metabolite, N‐Desmethyl‐Imatinib in Human Plasma

References

• Novartis and Glivec . 2001 . Summary of Product Characteristics .
   Google Scholar
• Cohen , M. H. , Williams , G. , Johnson , J. R. , Duan , J. , Gobburu , J. , Rahman , A. , Benson , K. , Leighton , J. , Kim , S. K. , Wood , R. , Rothmann , M. , Chen , G. , KM , U. , Staten , A. M. and Pazdur , R. 2002 . Approval summary for imatinib mesylate capsules in the treatment of chronic myelogenous leukemia . Clin. Cancer Res. , 8 : 935 – 942 .
   PubMed Web of Science ®Google Scholar
• Gschind , H. P. , Pfaar , U. , Waldmeir , F. , Zollinger , M. , Sayer , C. , Zbinden , P. , Hayes , M. , Pkorny , R. , Seiberling , M. , Ben‐Am , M. , Peng , B. and Gross , G. 2005 . Metabolism and disposition of imatinib mesylate in healthy volunteers . Drug Metab. Dispo. , 6 : 1503 – 1512 .
   Google Scholar
• Peng , B. , Hayes , M. , Resta , D. , Racine‐Poon , A. , Druker , B. J. , Talpaz , M. , Sawyers , C. L. , Rosamilia , M. , Ford , J. , Lloyd , P. and Capdeville , R. 2004 . Pharmacokinetics and pharmacodynamics of imatinib in a phase I trial with chronic myeloid leukemia patients . J. Clin. Oncol. , 22 : 935 – 942 .
   PubMed Web of Science ®Google Scholar
• Nimmanapalli , R. and Bhalla , K. 2002 . Mechanisms of resistance to imatinib mesylate in Bcr‐Abl‐positive leukemias . Curr. Opin. Oncol. , 14 : 616 – 620 .
   PubMed Web of Science ®Google Scholar
• Schleyer , E. , Pursche , S. , Kohne , C. H. , Schuler , U. , Renner , U. , Gschaidmeier , H. , Freiberg‐Richter , J. , Leopold , T. , Jenke , A. , Bonin , M. , Bergemann , T. , le Coutre , P. , Gruner , M. , Bornhauser , M. , Ottmann , O. G. and Ehninger , G. 2004 . Liquid chromatograpihic method detection and quantification of STI‐571 and its main metabolite N‐desmethyl‐STI in plasma, urine, cerebrospinal fluid, culture medium and cell preparations . J. Chromatogr. B , 799 : 23 – 36 .
   PubMed Web of Science ®Google Scholar
• Widmer , N. , Beguin , A. , Rochat , B. , Buclin , T. , Kovacsovics , T. , Duchosal , M. A. , Leyvraz , S. , Rosselet , A. , Biollaz , J. and Decosterd , L. A. 2004 . Determination of imatinib (Gleevec) in human plasma by solid‐phase extraction‐liquid chromatography‐ultraviolet absorbance detection . J. Chromatogr. B , 803 : 285 – 292 .
   PubMed Web of Science ®Google Scholar
• Velpandian , T. , Mathur , R. , Agarwal , N. K. , Arora , B. , Kumar , L. S. and Gupta , S. K. 2004 . Development and validation of a single liquid chromatographic method with ultraviolet detection for the determination of imatinib in biological samples . J. Chromatogr. B , 804 : 431 – 434 .
   PubMed Web of Science ®Google Scholar
• Bakhtiar , R. , Khemani , L. , Hayes , M. , Bedman , T. and Tse , F. 2002 . Quantification of the anti‐leukemia drug STI571 (Gleevec) and its metabolite (CGP 74588) in monkey plasma using a semi‐automated solid phase extraction procedure and liquid chromatography‐tandem mass spectrometry . J. Pharm. Biomed. Anal. , 28 : 1183 – 1194 .
   PubMed Web of Science ®Google Scholar
• Bakhtiar , R. , Lohne , J. , Ramos , L. , Khemani , L. , Hayes , M. and Tse , F. 2002 . High‐throughput quantification of the anti‐leukemia drug STI571 (Gleevec) and its main metabolite (cgp 74588) in human plasma using liquid chromatography‐tandem mass spectrometry . J. Chromatogr. B , 768 : 325 – 340 .
   PubMed Web of Science ®Google Scholar
• Parise , R. A. , Ramanathan , R. K. , Hayes , M. J. and Egorin , M. J. 2003 . Liquid chromatographic‐mass spectrometric assay for quantification of imatinib and its metabolite (CGP 74588) in plasma . J. Chromatogr. B , 791 : 39 – 44 .
   PubMed Web of Science ®Google Scholar
• Titier , K. , Picard , S. , Ducint , D. , Teilhet , E. , Moore , N. , Berthaud , P. , Mahon , F. and Molimard , M. 2005 . Quantification of imatinib in human plasma by high‐performance liquid chromatography‐tandem mass spectrometry . Ther. Drug Monit. , 27 : 634 – 640 .
   PubMed Web of Science ®Google Scholar
• Murall , M. and Rochat , B. 2006 . Fragmentation study of imatinib and characterization of new imatinib metabolites by liquid chromatography‐triple quadrupole and linear ion trap mass spectrometers . J. Mass Spectrom. , 41 : 390 – 404 .
   PubMed Web of Science ®Google Scholar
• “ US Food and Drug Administration, Guidance for industry, Bioanalytical Method Validation ” . http://www.fda.gov/cder/guidance/4252fnl.htm (accessed May 2004)
   Google Scholar
• 2003 . United States Pharmacopoeia XXXIII 2439 Rockville, MD : The United States Pharmacopeia Convention .
   Google Scholar
• Shah , V. P. , Midha , K. K. , Dighe , S. , McGilveray , I. J. , Skelly , J. P. , Yacobi , A. , Layloff , T. , Viswanathan , C. T. , Cook , C. E. , McDowall , R. D. , Pittman , K. A. and Spector , S. 1992 . Analytical methods validation: bioavailability, bioequivalence, and pharmacokinetic studies . J. Pharm. Sci. , 81 : 309 – 312 .
   Web of Science ®Google Scholar
• Bressolle , F. , Bromet‐Petit , M. and Audran , M. 1996 . Validation of liquid chromatographic and gas chromatographic methods. Applications in pharmacokinetics . J. Chromatogr. B , 686 : 3 – 10 .
   PubMed Web of Science ®Google Scholar
• Matuszewski , B. K. , Constanzer , M. L. and Chavez‐End , C. M. 1998 . Matrrix effect in quantitative LC/MS/MS analyses of biological fluids: a method for determination of finasteride in human plasma at picogram per mililiter concentrations . Anal. Chem. , 70 : 882 – 889 .
   PubMed Web of Science ®Google Scholar